Abstract:Abstract The G156A mutant of the DNA repair gene O6-methylguanine DNA-methyltransferase (MGMT) confers hematopoietic resistance to O6-benzylguanine (BG) combined with DNA-alkylating agents BCNU or temozolomide, and allows for selective in vivo expansion with drug administration of murine hematopoietic progenitors transduced with G156A MGMT retrovirus. Here we report our latest findings on retroviral vector copy number and insertion site analysis following drug treatment from a Phase I clinical trial utilizing MGMT-mediated chemoprotection for enhanced treatment of advanced solid tumors. Seven patients have entered the trial and 6 have completed the cell infusion process. For all patients, autologous CD34+ cells were transduced ex vivo with an MFG retroviral vector containing the G156A MGMT gene (packaged with PG13 by the National Gene Vector Laboratory, Ken Cornetta, Director) in the presence of the fibronectin fragment CH-296 and the cytokines SCF, Tpo, and Flt-3 ligand for 72 hours with three additions of retroviral supernatant. At 72 hours following patient treatment with BG and BCNU, cells were re-infused. Prior to infusion, the average vector copy number by quantitative real-time PCR analysis for six patients was 0.34 copies per genome, with an average of 24% of CFUs transduced by standard PCR for G156A MGMT, and an average of 9% of CD34+ cells expressing the MGMT transgene by flow cytometry. In one patient with metastatic melanoma we have further analysis of insertions. For this patient, the pre-infusion vector copy number of the bulk CD34+ population was 0.54 copies per genome by real-time PCR, with 27% of CFUs transduced and 8% of CD34+ cells expressing the MGMT transgene prior to infusion. Linear amplification-mediated (LAM)-PCR analysis of retroviral insertion sites in pre-infusion CFUs from this patient confirmed a polyclonal population, with an average of 1.6 retroviral insertions per positive CFU. In this patient, BG (120 mg/m2) and BCNU (33 mg/m2) were administered at 6 weeks post-infusion, and temozolomide (300 mg/day for 5 days) was administered at 13 weeks. Peripheral blood (PB) and bone marrow (BM) granulocyte and mononuclear cells (MNCs) were collected at weeks 5, 11, 15, and 16 for DNA and CFU analysis. Vector copy number at all post-infusion time points was below the limit of detection of SYBR Green probe-based real-time PCR (<100 copies of G156A MGMT per 5000 genomes). LAM-PCR detected the vector in post-treatment samples based on an internal vector control band present in BM MNCs at week 11 and in BM granulocytes at week 16, although specific insertion sites were not detected. Standard PCR revealed 1 out of 100 CFUs from week 11 BM MNCs contained the vector, with 2 out of 30 CFUs from week 15 PB MNCs. LAM-PCR in a subset of week 11 CFUs confirmed a single insertion site present in the same PCR-positive CFU. Sequence analysis of clonal vector insertions pre- and post-infusion is ongoing, and thus far a number of sites have been characterized, adding to the emerging database of clinical retroviral insertions. These are the first data to show emergence of transduced mutant MGMT cells after nonmyeloablative conditioning in humans and suggest that despite a low frequency of vector-marked hematopoietic cells, clinical in vivo drug selection can be observed.

Purine Salvage Rescue by Xanthine-Guanine Phosphoribosyltransferase (XGPRT) Potentiates Methotrexate Resistance Conferred by Transfer of a Mutated Dihydrofolate Reductase Gene.

Co-expression of the herpes simplex virus thymidine kinase gene potentiates methotrexate resistance conferred by transfer of a mutated dihydrofolate reductase gene

Protection of Marrow from Methotrexate Toxicity by Gene Transfer of Mutant Forms of Dihydrofolate Reductase into Hematopoietic Progenitor Cells

Post-Transplant Methotrexate Administration Leads to Improved Curability of Mice Bearing a Mammary Tumor Transplanted with Marrow Transduced with a Mutant Human Dihydrofolate Reductase Cdna

Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene.

Transfection With A Cdna-Encoding A Ser(31) Or Ser(34) Mutant Human Dihydrofolate-Reductase Into Chinese-Hamster Ovary And Mouse Marrow Progenitor Cells Confers Methotrexate Resistance

Transfection with a Cdna Encoding a Ser31 or Ser35 Mutant Human Dihydrofolate Reductase into Chinese Hamster Ovary and Mouse Marrow Progenitor Cells Confers Methotrexate Resistance

[In Vitro Cotransfer Human Multidrug Resistance Gene (Mdr-1) and Dihydrofolate Reductase Gene (DHFR) into Human CD(34)(+) Progenitor Cells to Broaden the Spectrum of Drug Resistance].

Expression of a Novel Double-Mutant Dihydrofolate Reductase-Cytidine Deaminase Fusion Gene Confers Resistance to Both Methotrexate and Cytosine Arabinoside.

Methotrexate reverses the drug resistance induced by PRPS1 gene mutation in acute lymphoblastic leukemia cells to 6-mercaptopurine

Effect of D, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol and tetrandrine on the reversion of multidrug resistance in K562/A02 cells.

Dihydrofolate reductase amplification and sensitization to methotrexate of methotrexate-resistant colon cancer cells

Increased Methotrexate Resistance and Dhfr Gene Amplification As a Consequence of Induced Ha-ras Expression in NIH 3T3 Cells.

Thymidine phosphorylase is both a therapeutic and a suicide gene in a murine model of mitochondrial neurogastrointestinal encephalomyopathy

Improvement of combination chemotherapy tolerance by introduction of polycistronic retroviral vector drug resistance genes MGMT and MDR1 into human umbilical cord blood CD34+ cells

Comparison of the Expression of a Mutant Dihydrofolate Reductase under Control of Different Internal Promoters in Retroviral Vectors

Non-invasive Molecular and Functional Imaging of Cytosine Deaminase and Uracil Phosphoribosyltransferase Fused with Red Fluorescence Protein

Chemoprotective Gene Transfer Ii: Multilineage in Vivo Protection of Haemopoiesis Against the Effects of an Antitumour Agent by Expression of A Mutant Human O-6-Alkylguanine-Dna Alkyltransferase

[A Bicistronic Retroviral Vector Containing MGMT and MDR1 Drug Resistance Genes Transfer into Human Umbilical Cord Blood CD34+ Cells to Improve Combination Chemotherapy Tolerance].

Reversal of P-gp Mediated Multidrug Resistance In-Vitro and In-Vivo by FG020318

Retrovirus Insertion Site Analysis Following In Vivo Drug Selection in a Phase I Clinical Trial Utilizing G156A MGMT for Enhanced Chemotherapy of Advanced Malignancies.